Strength: 200mg / 300mg
Pack Size: 1 x 14
Drug Class: antimetobolite and a demethylating agent
Dosage and Administration:
The recommended dosage of Auset is 200/300 mg orally once daily with or without food on Days 1 through 14 of each 28-day cycle. Continue Auset until disease progression or unacceptable toxicity.
Administer an antiemetic 30 minutes prior to each dose of Auset for the first 2 cycles. Antiemetic prophylaxis may be omitted after 2 cycles if there has been no nausea and vomiting.
Cold Storage: no
Auset is a prescription medicine used to treat symptoms of Acute Myeloid Leukemia. Auset may be used alone or with other medications. Auset is incorporated into DNA, where it reversibly inhibits DNA methyltransferase, thereby blocking DNA methylation.
Auset is indicated for continued treatment of adult patients with acute myeloid leukemia who achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy and are not able to complete intensive curative therapy.
Azacitidine is a pyrimidine nucleoside analog of cytidine that inhibits DNA/RNA methyltransferases. Azacitidine is incorporated into DNA and RNA following cellular uptake and enzymatic biotransformation to nucleotide triphosphates. Incorporation of azacitidine into the DNA of cancer cells in vitro, including acute myeloid leukemia cells, inhibited DNA methyltransferases, reduced DNA methylation and altered gene expression, including re-expression of genes regulating tumor suppression and cell differentiation. Incorporation of azacitidine into the RNA of cancer cells, including leukemic cells, inhibited RNA methyltransferases, reduced RNA methylation, decreased RNA stability and decreased protein synthesis
- Read the label carefully before use
- Keep out of the reach of children
- Do not exceed the recommended dose
Based on the mechanism of action and findings in animals, Auset can cause fetal harm when administered to a pregnant woman. Azacitidine administered to pregnant rats via a single intraperitoneal dose less than the recommended human daily dose of oral azacitidine on a mg/m2 basis caused fetal death and anomalies.
Advise patients of the risk of myelosuppression with Auset and of the need to monitor complete blood counts before and during treatment
Advise patients of the risk of gastrointestinal toxicity with Auset and of the potential need to use anti-emetic or anti-diarrheal medications during treatment
Advise women not to breastfeed during treatment with Auset and for 1 week after the last dose